A New Phase of Biopharmaceuticals

PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our proprietary elastin-like polypeptide (ELP) technology, which also serves as the engine for our preclinical pipeline.

Recent Highlights:

Learn more about PB1046, PhaseBio’s once weekly VIP analogue for pulmonary arterial hypertension, in these phaware® podcasts with Dr. Raymond Benza and Dr. Harold Palevsky